Statins could be as beneficial for people with acceptable cholesterol readings but high levels of inflammation as they are for those with high cholesterol levels, a new analysis finds.
"The JUPITER trial demonstrated that rosuvastatin, when given to apparently healthy men and women with low cholesterol but increased hs-CRP, reduced heart attack by 55 percent, stroke by 48 percent, angioplasty and bypass surgery by 46 percent and all-cause mortality by 20 percent – all highly significant – and did so in the absence of major side effects," said Dr Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston and a member of the JUPITER Study Group.
Circulation: Cardiology Quality and Outcomes.
'Number needed to treat'
Ridker and his colleagues calculated the absolute risk reduction and also used an epidemiological measure called "number needed to treat". That measure looks at the number of people who would need to be treated to prevent one additional bad outcome.
More may benefit from statins
Alhough the analysis was meant to help physicians and policymakers, it does have a take-home message for patients, one expert said.
Read more: Whole flaxseed cuts cholesterol